DK1851340T3 - Fremgangsmåde til diagnosticering og behandling af cancer ved anvendelse af b-catenin-splejsningsvarianter - Google Patents
Fremgangsmåde til diagnosticering og behandling af cancer ved anvendelse af b-catenin-splejsningsvarianterInfo
- Publication number
- DK1851340T3 DK1851340T3 DK06734945.6T DK06734945T DK1851340T3 DK 1851340 T3 DK1851340 T3 DK 1851340T3 DK 06734945 T DK06734945 T DK 06734945T DK 1851340 T3 DK1851340 T3 DK 1851340T3
- Authority
- DK
- Denmark
- Prior art keywords
- diagnostication
- catenin
- varieties
- cancer
- split
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65215405P | 2005-02-10 | 2005-02-10 | |
| US66708405P | 2005-03-30 | 2005-03-30 | |
| PCT/US2006/005032 WO2006086772A2 (en) | 2005-02-10 | 2006-02-10 | DIAGNOSING AND TREATING CANCER USING β-CATENIN SPLICE VARIANTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1851340T3 true DK1851340T3 (da) | 2013-03-11 |
Family
ID=36793829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06734945.6T DK1851340T3 (da) | 2005-02-10 | 2006-02-10 | Fremgangsmåde til diagnosticering og behandling af cancer ved anvendelse af b-catenin-splejsningsvarianter |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8110352B2 (da) |
| EP (1) | EP1851340B1 (da) |
| JP (1) | JP5031587B2 (da) |
| AU (1) | AU2006213610B2 (da) |
| CA (1) | CA2596845C (da) |
| DK (1) | DK1851340T3 (da) |
| HK (1) | HK1115165A1 (da) |
| WO (1) | WO2006086772A2 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110352B2 (en) * | 2005-02-10 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health & Human Services | Method of diagnosing and treating cancer using B-catenin splice variants |
| WO2008109369A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
| WO2009148623A2 (en) | 2008-06-05 | 2009-12-10 | Stc.Unm | Methods and related compositions for the treatment of cancer |
| NZ628463A (en) * | 2009-01-14 | 2015-12-24 | Us Health | Ratio based biomarkers and methods for use thereof |
| CA2860676A1 (en) | 2012-01-09 | 2013-07-18 | Novartis Ag | Organic compositions to treat beta-catenin-related diseases |
| WO2013154128A1 (ja) * | 2012-04-11 | 2013-10-17 | 塩野義製薬株式会社 | 新規動脈硬化症治療用医薬組成物及び動脈硬化症治療薬のスクリーニング方法 |
| WO2019014398A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF |
| WO2020014543A2 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1995013375A1 (en) * | 1993-11-10 | 1995-05-18 | The Johns Hopkins University | Tumor suppressor waf1 |
| AU6866198A (en) | 1997-03-24 | 1998-10-20 | Onyx Pharmaceuticals, Inc. | Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions |
| US6066500A (en) * | 1999-06-25 | 2000-05-23 | Isis Pharmaceuticals Inc. | Antisense modulation of Beta catenin expression |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| EP1272224A4 (en) * | 2000-03-31 | 2004-09-29 | Gene Logic Inc | GENE EXPRESSION PROFILES IN ESOPHAGIC TISSUE |
| JP4771576B2 (ja) * | 2000-06-12 | 2011-09-14 | 譲治 稲澤 | Ｇａｓｃ１遺伝子 |
| US20030064384A1 (en) | 2001-04-02 | 2003-04-03 | Mien-Chie Hung | Beta-catenin is a strong and independent prognostic factor for cancer |
| WO2003051905A2 (en) * | 2001-12-13 | 2003-06-26 | Exelixis, Inc. | Taojiks as modifiers of the beta-catenin pathway and methods of use |
| AU2003261101A1 (en) * | 2002-06-28 | 2004-01-19 | Hong Kong University Of Science And Technology | Plasma or serum marker and process for detection of cancer |
| EP1380644A1 (en) * | 2002-07-08 | 2004-01-14 | Kylix B.V. | The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role |
| US8110352B2 (en) * | 2005-02-10 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health & Human Services | Method of diagnosing and treating cancer using B-catenin splice variants |
-
2006
- 2006-02-10 US US11/883,694 patent/US8110352B2/en active Active
- 2006-02-10 AU AU2006213610A patent/AU2006213610B2/en active Active
- 2006-02-10 EP EP06734945A patent/EP1851340B1/en active Active
- 2006-02-10 JP JP2007555317A patent/JP5031587B2/ja not_active Expired - Fee Related
- 2006-02-10 CA CA2596845A patent/CA2596845C/en active Active
- 2006-02-10 WO PCT/US2006/005032 patent/WO2006086772A2/en active Application Filing
- 2006-02-10 DK DK06734945.6T patent/DK1851340T3/da active
-
2008
- 2008-04-30 HK HK08104793.3A patent/HK1115165A1/xx unknown
-
2012
- 2012-01-03 US US13/342,877 patent/US10000813B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1851340B1 (en) | 2013-01-30 |
| EP1851340A4 (en) | 2008-08-20 |
| US20120294929A1 (en) | 2012-11-22 |
| EP1851340A2 (en) | 2007-11-07 |
| AU2006213610B2 (en) | 2012-04-05 |
| CA2596845A1 (en) | 2006-08-17 |
| US8110352B2 (en) | 2012-02-07 |
| HK1115165A1 (en) | 2008-11-21 |
| US20090111762A1 (en) | 2009-04-30 |
| JP2008535474A (ja) | 2008-09-04 |
| CA2596845C (en) | 2016-11-08 |
| JP5031587B2 (ja) | 2012-09-19 |
| AU2006213610A1 (en) | 2006-08-17 |
| WO2006086772A2 (en) | 2006-08-17 |
| WO2006086772A3 (en) | 2007-05-10 |
| US10000813B2 (en) | 2018-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20200775A1 (no) | Fremgangsmåter og sammensetninger for behandling av kreft | |
| DK1851340T3 (da) | Fremgangsmåde til diagnosticering og behandling af cancer ved anvendelse af b-catenin-splejsningsvarianter | |
| DK1830838T3 (da) | Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme | |
| DK1888033T3 (da) | Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme | |
| DK1877232T3 (da) | Fremgangsmåde til behandling af træoverflader | |
| DK2155188T3 (da) | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft | |
| DK1853271T3 (da) | Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme | |
| DK1771201T3 (da) | Sammensætninger og fremgangsmåder til behandling eller forebyggelse af oxalat-relateret sygdom | |
| DK2340042T3 (da) | Fremgangsmåder og præparater til behandling af cancer | |
| DK3403657T3 (da) | Anvendelse af oligouronater til behandling af slimhyperviskositet | |
| DK2101819T3 (da) | Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis | |
| DK1888294T3 (da) | Fremgangsmåde til hårdlodning af artikler af rustfrit stål | |
| DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
| DK1824475T3 (da) | Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol | |
| DK1740197T3 (da) | Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki | |
| DK1611890T3 (da) | Fremgangsmåde til evaluering og behandling af cancer | |
| DK1868579T3 (da) | Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer | |
| DK2099796T3 (da) | Aza-indolyl-forbindelser og fremgangsmåder for anvendelse | |
| DK1899484T3 (da) | Identifikation af tumorer og væv | |
| DK1891208T3 (da) | Hidtil ukendte cellulære sammensætninger og fremgangsmåder til fremstilling deraf | |
| DK1781256T3 (da) | Phospholipid-gel-sammensætning til lægemiddelafgivelse og fremgangsmåder til behandling af sygdomme ved hjælp af samme | |
| DK2463283T3 (da) | Kondenserede heterocykliske phenylamidoforbindelser til forebyggelse og behandling af glucokinase-medierede sygdomme | |
| DK1644021T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme | |
| DK1706112T3 (da) | Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom | |
| DE602005016127D1 (de) | Substituierte hydantoine zur krebsbehandlung |